We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

80 hedge funds and large institutions have $93.1M invested in Pyxis Oncology in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,133% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $18K

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

11% more funds holding

Funds holding: 72 → 80 (+8)

8.29% more ownership

Funds ownership: 39.48% → 47.77% (+8.3%)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less capital invested

Capital invested by funds: $97.8M → $93.1M (-$4.7M)

Holders
80
Holders Change
+8
Holders Change %
+11.11%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
21
Reduced
20
Closed
16
Calls
$1.66M
Puts
$18K
Net Calls
+$1.64M
Net Calls Change
+$1.3M

Top Buyers

1
BlackRock
BlackRock
New York
+$10.4M
2
BOCH
Blue Owl Capital Holdings
New York
+$4.4M
3
Millennium Management
Millennium Management
New York
+$3.17M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.89M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.77M

Top Sellers

1
SC
Stempoint Capital
New York
-$2.49M
2
MIM
Monashee Investment Management
Massachusetts
-$1.89M
3
Goldman Sachs
Goldman Sachs
New York
-$923K
4
HF
HRT Financial
New York
-$592K
5
Jane Street
Jane Street
New York
-$589K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jones Financial Companies
76
Jones Financial Companies
Missouri
$1.66K +$2.1K +500 New
NA
77
NewEdge Advisors
Louisiana
$828 – – –
Northwestern Mutual Wealth Management
78
Northwestern Mutual Wealth Management
Wisconsin
$828 +$1.05K +250 New
MIM
79
Monashee Investment Management
Massachusetts
– -$1.89M -442,500 Closed
HF
80
HRT Financial
New York
– -$592K -139,142 Closed
CIC
81
Cornercap Investment Counsel
Georgia
– -$319K -74,903 Closed
Squarepoint
82
Squarepoint
New York
– -$291K -68,358 Closed
BHCM
83
Brevan Howard Capital Management
Jersey
– -$153K -35,987 Closed
PAS
84
Point72 Asia (Singapore)
Singapore
– -$127K -29,835 Closed
YIH
85
Y-Intercept (HK)
Hong Kong
– -$120K -28,053 Closed
NIM
86
NEOS Investment Management
Connecticut
– -$69.2K -16,238 Closed
SG Americas Securities
87
SG Americas Securities
New York
– -$59K -13,809 Closed
OAC
88
OMERS Administration Corp
Ontario, Canada
– -$50.3K -11,800 Closed
TRCT
89
Tower Research Capital (TRC)
New York
– -$41.3K -9,706 Closed
Citadel Advisors
90
Citadel Advisors
Florida
– -$17.3K -4,109 Closed
Macquarie Group
91
Macquarie Group
Australia
– -$5 -1,113 Closed
AF
92
Allworth Financial
California
– -$852 -200 Closed
WBC
93
West Branch Capital
Massachusetts
– -$107 -25 Closed
Fidelity Investments
94
Fidelity Investments
Massachusetts
– -$4 -1 Closed
T. Rowe Price Associates
95
T. Rowe Price Associates
Maryland
– +$66.1K +15,720 New
1 2 3
4

PYXS Hedge Fund Activity: Q2 2024 in Review

80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q2 2024, worth a combined $93.1M — down 4.8% from $97.8M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new PYXS positions and 16 closed out — a net gain of 9 holders — while 21 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $10.4M. The largest seller was Stempoint Capital, cutting an estimated $2.49M.

  • 80 institutional investors held Pyxis Oncology (PYXS) as of Q2 2024, up from 72 in Q1 2024.
  • Funds reported $93.1M of Pyxis Oncology stock for Q2 2024, down 4.8% quarter-over-quarter.
  • 25 funds opened new Pyxis Oncology positions in Q2 2024 and 16 closed out, a net change of +9 holders.
  • The largest Pyxis Oncology buyer in Q2 2024 was BlackRock, an estimated $10.4M added.
  • The largest Pyxis Oncology seller in Q2 2024 was Stempoint Capital, an estimated $2.49M sold.

Based on aggregated 13F filings for Q2 2024.